Bonn R
Department of Clinical Pharmacology, Schwarz GmbH, Monheim, Federal Republic of Germany.
Am J Cardiol. 1988 Mar 25;61(9):12E-14E. doi: 10.1016/0002-9149(88)90082-3.
A capsule formulation containing 50 mg of isosorbide mononitrate has been developed, 30% of which is in a nonsustained-release form to ensure rapid attainment of initial plasma levels. The remaining 70% is in a sustained-release form that ensures a long-lasting effect and the convenience of once-daily dosing. This formulation of sustained-release isosorbide mononitrate (Elantan LA 50 mg) provides plasma levels greater than 100 ng/ml for 17 hours after oral administration. For the remaining 7 hours, the nitrate plasma level ranges between 50 and 100 ng/ml.
已研发出一种含有50毫克单硝酸异山梨酯的胶囊制剂，其中30%为非缓释形式，以确保迅速达到初始血浆水平。其余70%为缓释形式，可确保长效作用并方便每日一次给药。这种缓释单硝酸异山梨酯制剂（依姆多50毫克）口服给药后17小时血浆水平高于100纳克/毫升。在其余7小时内，硝酸盐血浆水平在50至100纳克/毫升之间。
